About Potassium channel subfamily K member 12
Potassium channel subfamily K member 12 (KCNK12) is a protein
from Homo sapiens identified by UniProt accession
Q9HB15, 430 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Potassium channel subfamily K member 12 |
| UniProt accession | Q9HB15 |
| Gene | KCNK12 |
| Organism | Homo sapiens |
| Length | 430 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.33
- gut microbiome measurement · score 0.13
- hereditary neoplastic syndrome · score 0.12
- Inherited cancer-predisposing syndrome · score 0.12
- Lynch syndrome · score 0.12
- neurofibrillary tangles measurement · score 0.07
- glioblastoma multiforme · score 0.03
- ependymoma · score 0.03
- atypical teratoid rhabdoid tumor · score 0.02
- non-small cell lung carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HB15-F1 | alphafold | PREDICTED | 73.07 | — |
Amino-acid sequence (430 residues)
MSSRSPRPPP RRSRRRLPRP SCCCCCCRRS HLNEDTGRFV LLAALIGLYL VAGATVFSAL ESPGEAEARA RWGATLRNFS AAHGVAEPEL RAFLRHYEAA LAAGVRADAL RPRWDFPGAF YFVGTVVSTI GFGMTTPATV GGKAFLIAYG LFGCAGTILF FNLFLERIIS LLAFIMRACR ERQLRRSGLL PATFRRGSAL SEADSLAGWK PSVYHVLLIL GLFAVLLSCC ASAMYTSVEG WDYVDSLYFC FVTFSTIGFG DLVSSQHAAY RNQGLYRLGN FLFILLGVCC IYSLFNVISI LIKQVLNWML RKLSCRCCAR CCPAPGAPLA RRNAITPGSR LRRRLAALGA DPAARDSDAE GRRLSGELIS MRDLTASNKV SLALLQKQLS ETANGYPRSV CVNTRQNGFS GGVGALGIMN NRLAETSASR
Explore Potassium channel subfamily K member 12 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets